Results 281 to 290 of about 53,113 (297)

An update on the immune landscape in lung and head and neck cancers

Ca-A Cancer Journal for Clinicians, 2020
Jennifer W Carlisle, Taofeek Kunle Owonikoko, Nabil F Saba   +2 more
exaly  

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Nature Medicine, 2022
Jamie E Chaft, David J Kwiatkowski, Woo Yul Byun   +2 more
exaly  

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Nature Medicine, 2022
Edward S Kim, Vamsidhar Velcheti, Young Kwang Chae   +2 more
exaly  

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Nature Medicine, 2022
Solange Peters, Carlos Henrique Barrios, Melissa L Johnson   +2 more
exaly  

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Nature Medicine, 2018
David F Mcdermott, Mahrukh A Huseni, Michael B Atkins   +2 more
exaly  

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Nature Medicine, 2018
David R Gandara, Wei Zou, Achim Rittmeyer   +2 more
exaly  

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Nature Medicine, 2018
Elly L Van Der Veen, Marjolijn N Lub-De Hooge, Ronald Boellaard   +2 more
exaly  

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

Nature Medicine, 2019
Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida   +2 more
exaly  

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Lancet, The, 2020
Elizabeth A Mittendorf, Shigehira Saji, Kyung Hae Jung   +2 more
exaly  

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Lancet, The, 2016
Alexander Spira, Johan Filip Vansteenkiste, Julien Mazieres   +2 more
exaly